abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Company profile
Ticker
ABEO
Exchange
Website
CEO
Joao Siffert
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ACCESS PHARMACEUTICALS INC, CHEMEX PHARMACEUTICALS INC, PLASMATECH BIOPHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Abeona Therapeutics LLC • MacroChem Corporation ...
IRS number
830221517
ABEO stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
24 Apr 24
8-K
Abeona Therapeutics Provides Regulatory Update on Pz-cel
22 Apr 24
DEF 14A
Definitive proxy
19 Mar 24
8-K
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
18 Mar 24
10-K
2023 FY
Annual report
18 Mar 24
8-K
Abeona Therapeutics Announces $50 Million Credit Facility
8 Jan 24
8-K
Other Events
27 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
13 Nov 23
8-K
Changes in Registrant's Certifying Accountant
18 Oct 23
Transcripts
ABEO
Earnings call transcript
2023 Q3
13 Nov 23
ABEO
Earnings call transcript
2023 Q2
8 Aug 23
ABEO
Earnings call transcript
2023 Q1
24 May 23
ABEO
Earnings call transcript
2022 Q2
11 Aug 22
ABEO
Earnings call transcript
2022 Q1
17 May 22
ABEO
Earnings call transcript
2021 Q3
17 Nov 21
ABEO
Earnings call transcript
2021 Q2
29 Jul 21
ABEO
Earnings call transcript
2021 Q1
25 May 21
ABEO
Earnings call transcript
2020 Q4
25 Mar 21
ABEO
Earnings call transcript
2020 Q3
10 Nov 20
Latest ownership filings
4
Joseph Walter Vazzano
15 Mar 24
4
Brendan M. O'Malley
12 Mar 24
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
Flynn James E
12 Feb 24
4
Vishwas Seshadri
7 Feb 24
4
Mark Alvino
22 Jan 24
SC 13G/A
INTEGRATED CORE STRATEGIES (US) LLC
10 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.05 mm | 5.05 mm | 5.05 mm | 5.05 mm | 5.05 mm | 5.05 mm |
Cash burn (monthly) | 504.33 k | 501.75 k | 3.78 mm | 3.91 mm | 1.92 mm | 3.48 mm |
Cash used (since last report) | 3.47 mm | 3.45 mm | 25.98 mm | 26.86 mm | 13.17 mm | 23.94 mm |
Cash remaining | 1.58 mm | 1.60 mm | -20.93 mm | -21.81 mm | -8.12 mm | -18.89 mm |
Runway (months of cash) | 3.1 | 3.2 | -5.5 | -5.6 | -4.2 | -5.4 |
Institutional ownership, Q3 2023
95.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 43 |
Opened positions | 9 |
Closed positions | 7 |
Increased positions | 14 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 50.07 bn |
Total shares | 26.23 mm |
Total puts | 0.00 |
Total calls | 113.20 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Sco Capital Partners | 11.36 mm | $15.68 mm |
Adage Capital Partners GP, L.L.C. | 3.25 mm | $13.68 bn |
Nantahala Capital Management | 2.30 mm | $9.67 bn |
Flynn James E | 1.74 mm | $0.00 |
Point72 Asset Management | 1.18 mm | $4.97 bn |
AIGH Capital Management | 1.14 mm | $4.78 bn |
Millennium Management | 994.43 k | $4.19 bn |
Vanguard | 752.94 k | $3.17 bn |
Hirschman Orin | 652.17 k | $0.00 |
J. Goldman & Co | 495.34 k | $2.09 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Vazzano Joseph Walter | Common stock | Payment of exercise | Dispose F | No | No | 8.14 | 703 | 5.72 k | 228,260 |
4 Mar 24 | Brendan M. O'Malley | Common stock | Payment of exercise | Dispose F | No | No | 7.81 | 183 | 1.43 k | 180,118 |
6 Feb 24 | Vishwas Seshadri | Common Stock | Buy | Acquire P | No | No | 4.39 | 20,000 | 87.80 k | 528,260 |
17 Jan 24 | Mark Alvino | Common Stock | Sell | Dispose S | No | No | 5.11 | 7,084 | 36.20 k | 62,816 |
16 Oct 23 | Vishwas Seshadri | Common Stock | Payment of exercise | Dispose F | No | No | 4.14 | 181 | 749.34 | 508,260 |
News
Crude Oil Moves Higher; General Motors Earnings Top Views
23 Apr 24
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
23 Apr 24
Dow Jumps Over 200 Points; US Services PMI Falls In April
23 Apr 24
US Stocks Higher; PepsiCo Posts Upbeat Earnings
23 Apr 24
FDA Rejects Approval Of Abeona Therapeutics' Skin Disorder Treatment, Shares Sink
23 Apr 24
Press releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
25 Apr 24
Abeona Therapeutics Provides Regulatory Update on Pz-cel
22 Apr 24
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
18 Mar 24
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 Mar 24
Thinking about buying stock in Fusion Fuel Green, Tarena International, Ocugen, Akebia Therapeutics, or Abeona Therapeutics?
16 Feb 24